References

Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial

10.1001/jama.2023.19918 · ExternalCitation · doi-reference

Overall survival according to time‐of‐day of immunochemotherapy for extensive‐stage small cell lung cancer

10.1002/cncr.70126 · ExternalCitation · doi-reference

Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy

10.1016/j.cell.2024.04.015 · ExternalCitation · doi-reference

Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

10.1016/j.ejca.2023.01.007 · ExternalCitation · doi-reference

Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An in-depth chronotherapeutic study

10.1016/j.ejca.2024.113571 · ExternalCitation · doi-reference

Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study

10.1016/j.ejca.2025.115748 · ExternalCitation · doi-reference

Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis

10.1016/j.esmoop.2023.102220 · ExternalCitation · doi-reference

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

10.1016/s0140-6736(21)00797-2 · ExternalCitation · doi-reference

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study

10.1016/s1470-2045(21)00546-5 · ExternalCitation · doi-reference

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

10.1016/s1470-2045(23)00515-6 · ExternalCitation · doi-reference

Circadian control of the immune system

10.1038/nri3386 · ExternalCitation · doi-reference

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

10.1038/s41467-021-20935-9 · ExternalCitation · doi-reference

Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade

10.1038/s41590-024-01859-0 · ExternalCitation · doi-reference

Health effects of overweight and obesity in 195 countries over 25 years

10.1056/nejmoa1614362 · ExternalCitation · doi-reference

The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways

10.1073/pnas.1905080116 · ExternalCitation · doi-reference

Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle

10.1073/pnas.2214829120 · ExternalCitation · doi-reference

Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma

10.1093/oncolo/oyae197 · ExternalCitation · doi-reference

Clocks, cancer, and chronochemotherapy

10.1126/science.abb0738 · ExternalCitation · doi-reference

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

10.1136/jitc-2022-005920 · ExternalCitation · doi-reference

Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis

10.1136/jitc-2023-008011 · ExternalCitation · doi-reference

The mammalian circadian timing system: organization and coordination of central and peripheral clocks

10.1146/annurev-physiol-021909-135821 · ExternalCitation · doi-reference

Clocking cancer immunotherapy responses

10.1158/0008-5472.can-24-2083 · ExternalCitation · doi-reference

Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent antitumor effects of the PD-1/PD-L1 inhibitor BMS-1 in B16/BL6 melanoma-bearing mice

10.1158/1541-7786.mcr-21-0786 · ExternalCitation · doi-reference

Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer

10.1177/17588359251339921 · ExternalCitation · doi-reference

Balance diagnostics after propensity score matching

10.21037/atm.2018.12.10 · ExternalCitation · doi-reference

Current treatment and recent progress in gastric cancer

10.3322/caac.21657 · ExternalCitation · doi-reference

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21834 · ExternalCitation · doi-reference

Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis

10.3389/fimmu.2025.1653218 · ExternalCitation · doi-reference

The effect of inflammatory markers on the survival of advanced gastric cancer patients who underwent anti-programmed death 1 therapy

10.3389/fonc.2022.783197 · ExternalCitation · doi-reference